Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist Research Guide
Tirzepatide is a synthetic peptide notable for its dual mechanism — it activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual-agonist profile distinguishes it from single-receptor GLP-1 compounds and makes it a focal point of metabolic research.
What is Tirzepatide?
Tirzepatide mimics two incretin hormones — GIP and GLP-1 — both central to glucose regulation and appetite signaling. The combined activity is the basis of strong research interest in metabolic-model studies.
Mechanism of action
By binding and activating both GIP and GLP-1 receptors, Tirzepatide produces:
- Glucose-dependent insulin secretion — insulin release proportional to blood glucose.
- Reduced glucagon secretion — limiting hepatic glucose output.
- Appetite-signaling modulation — acting on central appetite-regulating regions.
- Improved insulin sensitivity — more efficient glucose utilization in research models.
What the research shows
The SURPASS clinical trial program has been the primary source of efficacy and safety data, consistently reporting substantial improvements in glycemic control and body-weight endpoints in study participants. Cardiovascular and long-term research is ongoing.
Sourcing in Canada
Source Tirzepatide only from reputable suppliers providing third-party purity testing and a Certificate of Analysis. Follow Health Canada research guidelines and aseptic reconstitution technique.
Browse research-grade Tirzepatide and related GLP-1 research compounds like Semaglutide and Retatrutide — all third-party tested to over 99% purity with a COA. Pair with bacteriostatic water for reconstitution.
This guide is part of our Peptides Canada research hub — explore the full library of compound guides.
Disclaimer: Educational and research content only. Tirzepatide is supplied strictly as a research chemical, not for human consumption or therapeutic use. All work must comply with Canadian regulations and institutional ethics approvals.